McKesson Corporation $MCK Stock: Candriam S.C.A. Reduces Stake

Posted by Brenda Bartman on Nov 8th, 2026

Candriam S.C.A. trimmed its holdings in McKesson Corporation (NYSE:MCK – Free Report) by 1.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 206,756 shares of the company’s stock after selling 3,654 shares during the quarter. McKesson makes up approximately 0.8% of Candriam S.C.A.’s portfolio, making the stock its 23rd largest holding. Candriam S.C.A.’s holdings in McKesson were worth $177,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in MCK. BlackRock Inc. bought a new stake in shares of McKesson during the second quarter valued at approximately $8,156,743,000. Bank of America Corp DE lifted its holdings in shares of McKesson by 2.4% in the first quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock worth $1,331,552,000 after buying an additional 35,916 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of McKesson by 3.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock worth $697,096,000 after acquiring an additional 29,747 shares during the last quarter. Legal & General Group Plc bought a new position in shares of McKesson during the second quarter worth $656,566,000. Finally, The Manufacturers Life Insurance Company purchased a new position in McKesson during the second quarter valued at $651,462,000. 85.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MCK. Evercore reiterated an “outperform” rating and issued a $950.00 price target (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Wells Fargo & Company increased their price objective on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a report on Thursday, August 6th. Citigroup raised their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,026.18.

Read Our Latest Stock Analysis on MCK

Insider Activity at McKesson

In other McKesson news, Director Bradley Lerman sold 301 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO B Jr sold 111 shares of McKesson stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares of the company’s stock, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,462 shares of company stock valued at $2,511,106 over the last 90 days. 0.06% of the stock is owned by corporate insiders.

McKesson Price Performance

Shares of MCK opened at $1,060.79 on Friday. The stock has a market capitalization of $122.48 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 2.08 and a beta of 0.27. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,121.50. The business’s 50 day simple moving average is $938.13 and its 200-day simple moving average is $868.12.

McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm had revenue of $110.96 billion during the quarter, compared to the consensus estimate of $109.90 billion. During the same period in the prior year, the company earned $9.86 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, sell-side analysts expect that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is presently 9.67%.

More McKesson News

Here are the key news stories impacting McKesson this week:

Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

About McKesson

(Free Report)

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.